SCHEMBL4110765

SCHEMBL4110765

CS(=O)(=O)NC(=O)C1CC1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 3/20 0.36
HTT P42858 2/20 0.36
NAMPT P43490 1/20 0.36
VCP P55072 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
HDAC8 Q9BY41 1/20 0.36
HDAC6 Q9UBN7 1/20 0.36
KMT2A Q03164 1/20 0.35
TP53 P04637 1/20 0.35
MAPT P10636 1/20 0.35
CA2 P00918 1/20 0.35
L3MBTL1 Q9Y468 3/20 0.34
HSD17B10 Q99714 1/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
USP2 O75604 1/20 0.34
LMNA P02545 1/20 0.34
GAA P10253 1/20 0.34
HPGD P15428 1/20 0.34
ALDH1A1 P00352 1/20 0.34
CYP2C19 P33261 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16508845 0.91 ALDH1A1 (0.39) POLBVCPKMT2AALDH1A1CYP2C19
SCHEMBL15931748 0.91 HDAC8 (0.43) HTTNPSR1HDAC8HDAC6L3MBTL1
SCHEMBL7695741 0.91 HDAC8 (0.48) NPSR1HDAC8HDAC6L3MBTL1HSD17B10
SCHEMBL29368888 0.89 SMN1; SMN2 (0.37) POLBHTTNAMPTVCPNPSR1
SCHEMBL19060 0.89 HDAC8 (0.52) HTTHDAC8HDAC6MAPTL3MBTL1
SCHEMBL16508912 0.86 VCP (0.39) VCPNPSR1KMT2ATP53MAPT
SCHEMBL15925040 0.86 GLA (0.49) POLBHTTVCPKMT2ASMN1; SMN2
SCHEMBL3223892 0.85 POLB (0.47) POLBVCPKMT2ASMN1; SMN2LMNA
SCHEMBL15165618 0.84 POLB (0.39) POLBNAMPTKMT2AL3MBTL1LMNA
SCHEMBL15431993 0.83 TP53 (0.41) POLBHTTNPSR1KMT2ATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11491157-B2 Cycloalkyl substituted pyrazolopyrimidines having activity against RSV Janssen Sciences Ireland Unlimited Company Co Cork, IE (IE) 2022-11-08 US claimed
EP-3774750-A1 IMMUNOMODULATORS, COMPOSITIONS AND METHODS THEREOF Betta Pharmaceuticals Co., Ltd (CN) 2021-02-17 EP claimed
WO-2019192506-A1 IMMUNOMODULATORS, COMPOSITIONS AND METHODS THEREOF BETTA PHARMACEUTICALS CO., LTD (CN) 2019-10-10 WO claimed
CN-104411692-A N-alkyltriazole compounds as lpar antagonists HOFFMANN LA ROCHE 2015-03-11 CN claimed
US-20090291921-A1 INTEGRASE INHIBITORS GILEAD SCIENCES, INC. (US) 2009-11-26 US claimed
WO-2009067541-A2 INTEGRASE INHIBITORS GILEAD SCIENCES, INC. (US) 2009-05-28 WO claimed
US-7312200-B2 9-ketospinosyn derivatives BAYER CROPSCIENCE AG (DE) 2007-12-25 US claimed
US-20060128642-A1 9-Ketospinosyn derivatives BAYER CROPSCIENCE AG (DE) 2006-06-15 US claimed
US-20240287029-A1 SULFONAMIDES, METHOD FOR PREPARATION THEREOF, AND USE THEREOF CHENGDU SHIBEIKANG BIOMEDICAL TECHNOLOGY CO., LTD. (CN) 2024-08-29 US disclosed
EP-4410786-A1 SULFONAMIDE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF Chengdu Shibeikang Biomedical Technology Co., Ltd. (CN) 2024-08-07 EP disclosed
CN-112424174-B Heterocyclic compounds useful in the treatment of disease 艾匹根生物技术有限公司 2024-02-27 CN disclosed
EP-3746444-B1 CYCLOALKYL SUBSTITUTED PYRAZOLOPYRIMIDINES HAVING ACTIVITY AGAINST RSV JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) 2023-09-27 EP disclosed
EP-3746444-B1 CYCLOALKYL SUBSTITUTED PYRAZOLOPYRIMIDINES HAVING ACTIVITY AGAINST RSV JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) 2023-09-27 EP disclosed
WO-2023046150-A1 SULFONAMIDE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF 成都施贝康生物医药科技有限公司 2023-03-30 WO disclosed
US-20140221340-A1 CHEMOKINE RECEPTOR ACTIVITY REGULATOR KYOWA HAKKO KIRIN CO., LTD. (JP) 2014-08-07 US disclosed
US-20140221340-A1 CHEMOKINE RECEPTOR ACTIVITY REGULATOR KYOWA HAKKO KIRIN CO., LTD. (JP) 2014-08-07 US disclosed
EP-2543670-A1 PYRAZOLOPYRIMIDINE DERIVATIVE Kyowa Hakko Kirin Co., Ltd. (JP) 2013-01-09 EP disclosed
WO-2011108689-A1 PYRAZOLOPYRIMIDINE DERIVATIVE 協和発酵キリン株式会社 (JP) 2011-09-09 WO disclosed
US-20090291921-A1 INTEGRASE INHIBITORS GILEAD SCIENCES, INC. (US) 2009-11-26 US disclosed
WO-2009067541-A2 INTEGRASE INHIBITORS GILEAD SCIENCES, INC. (US) 2009-05-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090291921-A1 INTEGRASE INHIBITORS TYMP, DNTT, PAICS POLB 12/4885HTT 4325/4885NAMPT 316/4885
US-20240287029-A1 SULFONAMIDES, METHOD FOR PREPARATION THEREOF, AND USE THEREOF P2RX3, P2RX5, P2RX2 POLB 4529/4885HTT 4628/4885NAMPT 693/4885
US-20060128642-A1 9-Ketospinosyn derivatives SNX9, NANS, BROX POLB 4656/4885HTT 1282/4885NAMPT 328/4885
US-11491157-B2 Cycloalkyl substituted pyrazolopyrimidines having activity against RSV ACE, ACE2, PTBP1 POLB 306/4885HTT 4123/4885NAMPT 799/4885
US-20140221340-A1 CHEMOKINE RECEPTOR ACTIVITY REGULATOR CXCR2, ACKR3, CCR2 POLB 2564/4885HTT 4833/4885NAMPT 1917/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.